 Company To Host an Investor Conference Call on Tuesday, March 30, 2021 at 8:00 AM EDT Pieris achieves 13 million milestone from AstraZeneca for initiation of PRS-060AZD1402 phase 2a study and AstraZeneca to purchase 10 million equity stake in Pieris common stock as part of an amended collaboration agreement 13 million equity investment by Seagen in Pieris, in addition to a clinical trial and supply agreement to evaluate cinrebafusp alfa PRS-343 in combination with TUKYSA tucatinib in HER2-low gastric cancer as part of an amended collaboration agreement Additional clinical benefit and safety data from the highest dose cohort and updated biomarker data across all active dose cohorts from cinrebafusp alfa phase 1 monotherapy study to be presented at American Association for Cancer Research Annual Meeting 2021 Synergistic preclinical PRS-344 data to be presented at American Association for Cancer Research Annual Meeting 2021, including in vitro data evaluating potential effects of combining 4-1BB with PD-L1 and the effects of PRS-344 on CD8 T cells, as well as dose-dependent anti-tumor response in in vivo preclinical models BOSTON, MA ACCESSWIRE March 30, 2021 Pieris Pharmaceuticals, Inc. NASDAQ:PIRS, a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin technology platform for respiratory diseases, cancer, and other indications, today reported financial results for the fiscal year ended December 31, 2020 and provided an update on the Companys recent and anticipated future developments. We are pleased to announce the achievement of our second clinical milestone for PRS-060AZD1402, triggered by the initiation of phase 2a by our partner, AstraZeneca, who further demonstrated their commitment to our respiratory-focused alliance with an equity investment, said Stephen S. 